Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment

Shanghai Junshi Biosciences

25/11/2025 05:44

** Hong Kong-listed shares of Shanghai Junshi Biosciences 1877.HK rise 5.9% to HK$25.2, their biggest intraday pct gain since October 31

** Stock touches its highest level since November 18, and set for a second session of gains

** Shanghai-listed shares 688180.SS climb 3.5% to 37.52 yuan, their highest point since November 19

** The China-based innovative drug developer plans to submit new drug application of its product toripalimab injection (code: JS001sc) to regulatory authorities in the near future

** JS001sc is a subcutaneous injection for treatment of recurrent or metastatic non-squamous non-small cell lung cancer

** Phase III clinical study of JS001sc for the first-line treatment of non-squamous non-small cell lung cancer has met the primary endpoints, says Shanghai Junshi

** YTD, Hong Kong stock up 114.9%, Shanghai-listed shares up 36.9%, Hang Seng Biotech Index .HSBIO up 81.5%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))